/DISREGARD RELEASE: AIkido Pharma Inc./
Rhea-AI Impact
Rhea-AI Sentiment
We are advised by AIkido Pharma Inc. that journalists and other readers should disregard the news release, AIkido Pharma Announces Strategic Investment in Social Communications Platform Provider Discord, Inc., issued 04-May-2022 over PR Newswire. The release was issued in error.
SOURCE AIkido Pharma Inc.
aiki
NASDAQ:AIKI
AIKI Rankings
AIKI Latest News
AIKI Stock Data
About AIKI
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.